Edgewise Therapeutics reports Q4 EPS (47c), consensus (44c)

Cash, cash equivalents and marketable securities were approximately $530.1M as of December 31, 2025. “Following strong execution in 2025, we have entered a transformative year,” said CEO Kevin Koch. “We remain on track to deliver pivotal GRAND CANYON top-line data for sevasemten, with the potential to support the first marketing application for the treatment of Becker. We also expect CIRRUS-HCM 12-week Part D results for EDG-7500 in HCM in the first half of 2026. Data from Part D will support refinement of our Phase 3 trial strategy in HCM. With multiple near-term catalysts and a high-performing team, we are closer than ever to delivering transformative medicines for patients living with serious conditions that still lack adequate treatment options and represent significant unmet medical needs.”